BioDlink International Co (HKSE:01875) ROCE %: -18.89% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01875 BioDlink International Co Ltd HKSE:01875
62 GF Score
Price HK$4.02
GF Value HK$1.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BioDlink International Co ROCE %?

BioDlink International Co HKSE:01875 62 ROCE % is -18.89% as of Dec. 2025. GuruFocus rates HKSE:01875 with a GF Score™ of 62/100 and a GF Value™ of HK$1.47 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioDlink International Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -18.89%.

BioDlink International Co  (HKSE:01875) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioDlink International Co ROCE % Related Terms

BioDlink International Co ROCE % Historical Data

* Premium members only.

The historical data trend for BioDlink International Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioDlink International Co ROCE % Chart

BioDlink International Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -50.78 -5.87 -3.18 4.13 -8.66

BioDlink International Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.76 6.61 1.68 1.91 -18.89
HKSE:01875
62GF Score
BioDlink International Co Ltd HKSE:01875
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioDlink International Co ROCE % Calculation

BioDlink International Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-97.71/( ( (1610.874 - 443.471) + (1391.168 - 302.159) )/ 2 )
=-97.71/( (1167.403+1089.009)/ 2 )
=-97.71/1128.206
=-8.66 %

BioDlink International Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-218.46/( ( (1613.816 - 389.668) + (1391.168 - 302.159) )/ 2 )
=-218.46/( ( 1224.148 + 1089.009 )/ 2 )
=-218.46/1156.5785
=-18.89 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -18.89% mean?
BioDlink International Co (HKSE:01875) has a ROCE % of -18.89% as of Dec. 2025.
Is BioDlink International Co's ROCE % too high?
BioDlink International Co's current ROCE % is -18.89%. Overall, BioDlink International Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioDlink International Co's ROCE % compare to VRTX and REGN?
BioDlink International Co's ROCE % of -18.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BioDlink International Co's current ROCE % is -18.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioDlink International Co stock overvalued right now?
Based on GuruFocus' analysis, BioDlink International Co (HKSE:01875) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.47, compared to a current price of HK$4.02 — trading 173.5% above its estimated fair value. The current ROCE % is -18.89%. BioDlink International Co's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BioDlink International Co (HKSE:01875), the current ROCE % is -18.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioDlink International Co (HKSE:01875) Overvalued in 2026?

Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued. The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47. GuruFocus considers BioDlink International Co to be Significantly Overvalued.

Key valuation signals for HKSE:01875:

  • ROCE %: -18.89%
  • GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioDlink International Co Business Description

Address 120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
62GF Score

Get the complete analysis for HKSE:01875

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.02
Price
HK$1.47
GF Value